RxDoctor Payments Data

Nenad Bugarija, MD

Internal Medicine · Seven Fields, PANPI 1770646648

Payments from drug & device makers

$1,141in general payments, 2019–2025

Across 16 payments — averaging $71.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$207
  • Johnson & Johnson$199
  • Novo Nordisk$138
  • GSK$125
  • Amgen$122
  • E.r. Squibb & Sons, L.L.C.$121
  • plus $228 from 2 others

What the payments were for

  • Speaking & faculty fees$11010%
  • Food & beverage$1,03190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie7$207
Johnson & Johnson2$199
Novo Nordisk2$138
GSK1$125
Amgen1$122
E.r. Squibb & Sons, L.L.C.1$121
Lilly USA, LLC1$118
Sanofi1$110

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,141 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$124,296
Medicare patients
406
Services billed
1,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$248,323
TrulicityDulaglutide135$136,130
JardianceEmpagliflozin119$117,368
XareltoRivaroxaban86$84,014
TradjentaLinagliptin99$73,682
Breo ElliptaFluticasone/Vilanterol98$43,881
OzempicSemaglutide43$41,048
MounjaroTirzepatide31$31,205
Glatiramer Acetate11$30,687
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$24,673
JanuviaSitagliptin Phosphate12$16,149
Lantus SolostarInsulin Glargine,hum.Rec.Anlog100$15,775
CreonLipase/Protease/Amylase35$14,204
Tiotropium Bromide26$14,174
LinzessLinaclotide14$13,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$118$167,335166 claims
Johnson & JohnsonXarelto$199$84,01486 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$125$82,068153 claims
Novo NordiskOzempic$138$41,04843 claims
AbbVieCreon, Linzess, Synthroid$207$34,678153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Seven Fields

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →